Harut Madatovian, DO
Sports Medicine · Pasadena, CANPI 1225433006
Payments from drug & device makers
Across 64 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$305
- Cranial Technologies, Inc$160
- Amgen$131
- Novo Nordisk$118
- Merck$86
- Hologic Sales And Service, LLC$80
- plus $624 from 16 others
What the payments were for
- Food & beverage$1,504100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $305 |
| Cranial Technologies, Inc | 10 | $160 |
| Amgen | 6 | $131 |
| Novo Nordisk | 6 | $118 |
| Merck | 5 | $86 |
| Hologic Sales And Service, LLC | 3 | $80 |
| Lilly USA, LLC | 3 | $72 |
| Ardelyx, Inc. | 2 | $67 |
| GSK | 2 | $57 |
| Sanofi Pasteur Inc. | 3 | $52 |
| Amarin Pharma, Inc. | 2 | $49 |
| Inspire Medical Systems, Inc. | 1 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| Johnson & Johnson | 1 | $34 |
| Incyte Corporation | 1 | $28 |
| Amneal Pharmaceuticals LLC | 1 | $26 |
| Ironwood Pharmaceuticals, Inc | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $25 |
| Pfizer | 1 | $23 |
| Exact Sciences | 1 | $23 |
| Dexcom, Inc. | 1 | $20 |
How this compares
$1,504 in reported general payments places this provider in the 45th percentile of 662 sports medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $141,611 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 21 | $42,109 |
| MounjaroTirzepatide | 37 | $39,069 |
| TrulicityDulaglutide | 34 | $31,871 |
| EliquisApixaban | 34 | $23,723 |
| JanuviaSitagliptin Phosphate | 17 | $21,695 |
| Chlorzoxazone | 12 | $13,745 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 42 | $13,533 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $12,862 |
| Icosapent Ethyl | 79 | $12,649 |
| Dexlansoprazole DrDexlansoprazole | 49 | $11,576 |
| FarxigaDapagliflozin Propanediol | 17 | $11,177 |
| Diclofenac Sodium | 75 | $8,745 |
| VascepaIcosapent Ethyl | 20 | $6,705 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $6,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $118 | $141,611155 claims |
| Lilly USA, LLCMounjaro, Trulicity | $72 | $70,94171 claims |
| MerckJanuvia, Janumet | $86 | $34,55733 claims |
| PfizerEliquis | $23 | $23,72334 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $26 | $1,341138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 662 sports medicine providers in California.
Other sports medicine in Pasadena
- Gregory AdamsonPasadena$86K
- Neal ElattracheLos Angeles$51M
- Nathaniel CohenLos Gatos$6.4M
- Thomas KnappSanta Monica$2.5M
- Seth ShermanStanford$1.8M
- Michael FreehillStanford$1.7M
- Deryk JonesSan Carlos$1.6M
- Allan MishraMenlo Park$1.5M
- Heinz Hoeneckela Jolla$1.4M
- Marc SafranPalo Alto$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.